Ledipasvir And Sofosbuvir

Introduction Overview

Generic Name

ledipasvir and sofosbuvir

Brand Name

Harvoni

Dosage Form

oral tablets, oral pellets

Drug Class

Antiviral combinations

Pharmacokinetics

Absorption:
Harvoni’s active components, ledipasvir and sofosbuvir, are administered orally with bioavailability influenced by food intake. Ledipasvir exhibits moderate solubility in acidic conditions, and food enhances its absorption, improving the pharmacokinetic profile. Sofosbuvir is rapidly absorbed with peak plasma concentrations observed in about 0.5 to 2 hours post-dose. The presence or absence of food does not significantly affect overall exposure to sofosbuvir or ledipasvir in tablet form. However, when administered as oral pellets, ledipasvir and sofosbuvir can be taken with or without food; nonetheless, co-administration with acidic foods or beverages should be avoided to maintain optimal drug absorption. The combination of these agents allows for efficient oral absorption suitable for once-daily dosing.

Distribution:
Upon absorption, ledipasvir is highly protein-bound (>99.8%), mainly to plasma proteins, which impacts its distribution volume and prolongs systemic exposure. Sofosbuvir, in contrast, has lower protein binding (~61%–65%); its active metabolite, GS-461203, exhibits intracellular accumulation in hepatocytes where viral replication occurs. The volume of distribution for ledipasvir suggests limited tissue penetration outside the liver, which is the primary site of infection. Sofosbuvir and its metabolites distribute well into liver cells, optimizing antiviral activity. Pharmacokinetic studies indicate no significant accumulation with repeated dosing, and the distribution pattern complements their mechanisms targeting intracellular viral replication.

Metabolism:
Sofosbuvir is a nucleotide analog prodrug extensively metabolized intracellularly in hepatocytes to its pharmacologically active triphosphate metabolite (GS-461203) via enzymatic hydrolysis, phosphorylation, and subsequent metabolism involving CES1, HINT1, and nucleotidases. Its inactive metabolite, GS-331007, is generated through dephosphorylation and constitutes the major circulating metabolite in plasma. Ledipasvir undergoes minimal metabolism and is primarily eliminated unchanged via the fecal route. Neither component is substantially metabolized by cytochrome P450 enzymes, reducing the risk of significant CYP-mediated drug interactions. This metabolic profile allows for predictable pharmacokinetics with low interindividual variability.

Elimination:
Sofosbuvir’s predominant route of elimination is renal excretion of the inactive metabolite GS-331007, accounting for approximately 80% of the administered dose. Less than 1% of sofosbuvir is excreted unchanged in urine. Ledipasvir is mainly excreted via feces as unchanged drug, with minimal urinary excretion. The elimination half-life of sofosbuvir is approximately 0.5 hours, while the active intracellular metabolite has a longer half-life supporting sustained antiviral effects. Ledipasvir has a plasma elimination half-life of approximately 47 hours, facilitating once-daily dosing. Renal impairment does not significantly affect ledipasvir levels but leads to increased systemic exposure of sofosbuvir’s metabolites, necessitating careful patient monitoring. Hepatic impairment has variable effects, and cautious use is warranted in decompensated cirrhosis. Overall, Harvoni’s elimination profiles favor convenience and sustained antiviral activity with a low dosing frequency.

Dosage Forms

Available Dosage Forms:
Harvoni is commercially available in the following formulations:
- Oral tablets containing 90 mg ledipasvir and 400 mg sofosbuvir
- Oral tablets containing 45 mg ledipasvir and 200 mg sofosbuvir
- Oral pellets containing 45 mg ledipasvir and 200 mg sofosbuvir
- Oral pellets containing 33.75 mg ledipasvir and 150 mg sofosbuvir

Dosages for Adults and Adolescents:
For adults and adolescents (≥12 years or weighing at least 35 kg) with chronic hepatitis C virus (HCV) infection genotypes 1, 4, 5, or 6, the recommended dosage is:
- 1 tablet of Harvoni 90 mg/400 mg orally once daily for 12 weeks.
Dosage duration can vary based on HCV genotype, presence of cirrhosis (compensated or decompensated), prior treatment history, and co-administration with ribavirin.

In special cases such as decompensated cirrhosis and post-liver transplant patients, Harvoni is often used in combination with ribavirin, with dosing tailored by the treating physician.

Specific Patient Populations:
Pediatric Patients:
- For children aged 3 years and older, Harvoni dosing is weight-based using oral pellets or tablets.
- Pellets are particularly beneficial for children with difficulty swallowing tablets.
- Dosage adjustments are made based on the child’s weight, as per prescribing guidelines.

Renal Impairment:
- No dosage adjustments are generally required in patients with mild to moderate renal impairment.
- Use caution in patients with severe renal impairment or end-stage renal disease, as sofosbuvir metabolites accumulate.

Hepatic Impairment:
- Use in patients with compensated cirrhosis (Child-Pugh A) is supported without dose adjustment.
- In decompensated cirrhosis (Child-Pugh B or C), use Harvoni in combination with ribavirin with close monitoring.

In summary, Harvoni dosage forms and regimens are designed to support effective antiviral therapy across age groups and liver disease severities with flexibility for individualized treatment planning.

Mechanism Of Action

Harvoni is a fixed-dose combination antiviral therapy consisting of ledipasvir and sofosbuvir, each targeting essential viral proteins critical for hepatitis C virus (HCV) replication and lifecycle.

Ledipasvir acts as an inhibitor of the NS5A protein, a multifunctional nonstructural HCV protein pivotal for viral RNA replication and assembly of the viral replication complex. By binding to NS5A, ledipasvir disrupts the viral replication machinery, preventing the formation of new viral RNA and impairing virion assembly and release. This blockade effectively reduces viral load by interrupting an essential protein interaction required for the hepatitis C virus lifecycle.

Sofosbuvir is a nucleotide analog prodrug that is intracellularly metabolized to its active uridine analog triphosphate. It functions as a potent inhibitor of the NS5B RNA-dependent RNA polymerase, the key enzyme responsible for synthesizing the viral RNA genome. Incorporation of the active metabolite into the viral RNA chain results in premature chain termination, halting viral replication. This direct inhibition effectively blocks HCV RNA synthesis across multiple genotypes.

The complementary action of ledipasvir and sofosbuvir targets separate essential viral proteins, providing a potent dual mechanism that significantly suppresses HCV replication. This synergistic blockade results in high rates of sustained virologic response after treatment, effectively curing the infection in most patients.

Clinical studies have demonstrated that this combination therapy achieves viral clearance in over 90% of treated individuals with genotype 1 and other sensitive genotypes, with improved safety and tolerability profiles compared to interferon-based regimens. Furthermore, Harvoni’s mechanism allows it to avoid the side effects associated with nonspecific immune activation, highlighting its therapeutic advancement over earlier hepatitis C treatments.

Pharmacological Actions

Potent inhibition of hepatitis C virus (HCV) replication through NS5A protein blockade (ledipasvir).
Selective inhibition of HCV RNA-dependent RNA polymerase NS5B, resulting in premature viral RNA chain termination (sofosbuvir).
Synergistic antiviral effect due to dual targeting of distinct viral replication proteins.
Oral antiviral activity effective against multiple HCV genotypes, particularly genotypes 1, 4, 5, and 6.
High cure rates in chronic hepatitis C infection with a short, once-daily dosing regimen.
Reduced systemic toxicity compared to interferon-based treatments.
Minimal induction of host immune response, limiting inflammatory side effects.
Metabolic stability allowing effective intracellular delivery of active metabolites.
Low potential for CYP450-mediated drug interactions enhancing clinical safety.
Effective in both treatment-naïve and previously treated patients with compensated and selected decompensated liver disease.
Capability to overcome resistance-associated variants due to combination antiviral action.
Improved patient adherence due to convenient oral dosing and favorable safety profile.

Therapeutic Or Clinical Uses

Treatment of chronic hepatitis C virus (HCV) infection genotypes 1, 4, 5, or 6.
Use in adults and pediatric patients aged 3 years and older for chronic HCV infection.
Treatment of HCV infection in patients without cirrhosis or with compensated cirrhosis.
Use in combination with ribavirin for HCV genotype 1 infection with decompensated cirrhosis.
Therapy for patients with HCV infection who have undergone liver transplantation.
Part of interferon-free direct-acting antiviral regimens for enhanced tolerability.
Management of treatment-naïve and previously treated HCV patients to achieve sustained virologic response.
Use as an oral once-daily regimen simplifying treatment and improving adherence.
Treatment for co-infected individuals with careful monitoring for hepatitis B virus reactivation.
Preferred agent in clinical guidelines for eligible HCV genotypes based on efficacy and safety.
Reduction of liver inflammation and potential for cirrhosis progression by viral eradication.
Decrease in risk of HCV-related hepatocellular carcinoma following viral clearance.
Facilitation of liver transplantation candidacy by improving liver function status.
Management of chronic HCV in patients with HIV co-infection with adjusted monitoring.
Availability of generic formulations increasing patient accessibility.

Side Or Adverse Effects

Fatigue and tiredness, commonly mild to moderate in severity.
Headache, frequently reported during treatment.
Weakness and asthenia.
Risk of hepatitis B virus (HBV) reactivation in coinfected patients leading to severe liver injury.
Bradycardia, particularly when co-administered with amiodarone, with potential fatal outcomes.
Gastrointestinal symptoms including nausea and diarrhea, less commonly observed.
Potential for anemia and teratogenic effects when combined with ribavirin.
Elevated liver enzymes in rare cases, indicating hepatic stress or injury.
Skin reactions such as rash or pruritus reported occasionally.
Insomnia or sleep disturbances in a subset of patients.
Rare cases of fatigue-associated dizziness or lightheadedness.
Hypersensitivity reactions including rare anaphylaxis.
Possible reactivation of latent infections other than HBV reported infrequently.
No significant nephrotoxicity identified, but monitoring advised in patients with renal impairment.
Post-treatment laboratory abnormalities including bilirubin elevation and lipase changes in some cases.

Precautions

Screen all patients for hepatitis B virus infection prior to initiation due to risk of HBV reactivation.
Avoid coadministration with amiodarone to prevent severe bradycardia.
Use ribavirin with caution due to its teratogenic potential; ensure effective contraception in men and women.
Monitor liver function tests and viral load regularly during therapy.
Assess renal function before and during treatment, especially in patients with pre-existing renal impairment.
Caution in patients with decompensated cirrhosis; therapy often combined with ribavirin under expert supervision.
Evaluate potential drug interactions, particularly with P-glycoprotein and CYP inducers.
Avoid simultaneous administration of antacids or proton pump inhibitors within timing recommendations to preserve absorption.
Instruct patients on adherence to prevent viral resistance and treatment failure.
Monitor heart rate and symptoms of bradycardia especially in patients on concomitant heart medications.
Use caution in pediatric patients under 3 years; safety and effectiveness not established.
Consider therapeutic options carefully in pregnant or breastfeeding women due to insufficient safety data.
Avoid dose modifications or treatment interruption without consultation with healthcare provider.
Use appropriate sterile technique when administering oral pellets mixed with food to avoid contamination.
Educate patients on safe practices to prevent HCV transmission despite treatment.

Warnings

Boxed Warning for the risk of hepatitis B virus (HBV) reactivation which may lead to fulminant hepatitis, hepatic failure, or death.
Severe bradycardia and heart block reported when coadministered with amiodarone; avoid combination unless no alternatives.
Birth defects and fetal death risk with ribavirin coadministration necessitate effective contraception during and six months post-treatment.
Potential for worsening liver function or liver failure, especially in pre-existing liver disease or decompensated cirrhosis.
Not established for safety and efficacy in children under 3 years of age.
Possible immune reactivation phenomena after HCV clearance requiring close clinical monitoring.
May cause serious hypersensitivity reactions including rash, angioedema, and anaphylaxis.
Risk of drug interactions that could reduce efficacy or increase toxicity; careful medication review required.
Avoid abrupt discontinuation to prevent viral rebound or resistance development.
Use caution in patients with severe renal impairment due to elevated circulating metabolite levels.
Potential for rare cases of liver cancer reported; risk-benefit assessment recommended in high-risk patients.
Inadequate response in certain HCV genotypes not covered by Harvoni necessitates genotype testing prior to therapy.
Patients should be advised on the risk of continued transmission of HCV despite treatment.
Increased monitoring may be necessary for patients co-infected with HIV or other comorbid conditions.
Known hypersensitivity to ledipasvir, sofosbuvir, or any excipients contraindicates use.

Contraindication

Known hypersensitivity or allergic reactions to ledipasvir, sofosbuvir, or any component of the formulation.
Co-administration with amiodarone due to risk of life-threatening bradycardia is contraindicated unless absolutely necessary with monitoring.
Use of Harvoni in patients with significant hypersensitivity reactions to previous nucleotide analog treatments.
Patients with concurrent use of strong P-gp inducers (e.g., rifampin, St. John’s wort, carbamazepine) which may significantly reduce drug levels.
Pregnant women when used in combination with ribavirin, due to teratogenicity and fetal toxicity risks.
Use in children under 3 years of age where safety and efficacy have not been established.
Patients with decompensated cirrhosis not receiving medical supervision and combination treatment as indicated.
Concomitant use with proton pump inhibitors or antacids not separated by time according to recommendations as it decreases absorption.
Patients with end-stage renal disease or severe renal impairment when benefits do not outweigh risks due to metabolite accumulation.
Use with other drugs that prolong QT interval or cause serious arrhythmias without strict cardiac monitoring.
Patients with complicated liver disease or uncontrolled infections posing high treatment risk without specialist care.
Concomitant use with experimental or unapproved antiviral agents lacking safety data in combination with Harvoni.

Drug Interactions

Amiodarone: Concomitant use may cause life-threatening bradycardia; generally contraindicated.
P-glycoprotein inducers (e.g., rifampin, St. John’s wort, carbamazepine): reduce Harvoni plasma concentrations leading to loss of efficacy; avoid combination.
Moderate to strong CYP450 inducers: may decrease ledipasvir and sofosbuvir levels; use not recommended.
Proton pump inhibitors (e.g., omeprazole) and antacids: decrease ledipasvir absorption; space administration by at least 4 hours.
HMG-CoA reductase inhibitors (statins): potential interaction increasing statin concentrations; monitor for adverse effects.
Immunosuppressants in transplant recipients (e.g., tacrolimus, cyclosporine): increased exposure may occur; therapeutic drug monitoring recommended.
Antiretrovirals for HIV: interactions vary; some may require dosage adjustment or avoidance.
Direct oral anticoagulants and warfarin: hepatic function changes may necessitate monitoring and dose adjustment.
Other antiviral agents including interferons or ribavirin: combination usage required based on clinical indication with monitoring.
Herbal supplements (e.g., Echinacea, St. John’s wort): potential induction of metabolizing enzymes; avoid to prevent reduced efficacy.
Antiepileptics such as phenytoin and carbamazepine: enzyme induction reduces Harvoni effectiveness.
Antibiotics like rifampin and rifabutin: potent enzyme induction reducing Harvoni exposure.
Acid-reducing agents: antacids administered simultaneously can reduce ledipasvir absorption.
Medications altering P-gp or OATP transporters: potential impact on ledipasvir/sofosbuvir pharmacokinetics.
Caution when used with drugs that affect heart rate or conduction due to possible additive effects with amiodarone.

Preparations Of The Drug

Harvoni tablets: Fixed-dose combination tablets containing 90 mg ledipasvir and 400 mg sofosbuvir, film-coated for oral administration.
Harvoni tablets: Lower-strength film-coated tablets containing 45 mg ledipasvir and 200 mg sofosbuvir for pediatric or dose-adjusted use.
Harvoni oral pellets: Small packets containing 45 mg ledipasvir and 200 mg sofosbuvir granules for oral suspension and suitable for children with swallowing difficulty.
Harvoni oral pellets: Another strength containing 33.75 mg ledipasvir and 150 mg sofosbuvir granules enabling flexible pediatric dosing.
Tablets formulated with inactive ingredients including colloidal silicon dioxide, copovidone, croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and film coating with polyethylene glycol, polyvinyl alcohol, titanium dioxide, and colorants in specific formulations.
Oral pellets prepared with excipients such as amino-methacrylate copolymer, hypromellose, iron oxide pigments, and other pharmaceutical-grade diluents to maintain stability and bioavailability.
Packaging: Tablets are supplied in bottles with child-resistant caps; pellets supplied in sealed packets within cartons with tamper-evident seals.
Storage recommendations include maintaining temperature below 86°F (30°C) and protecting from moisture to preserve drug integrity.
Manufactured by Gilead Sciences, Inc., with generic versions produced by subsidiary Asegua Therapeutics LLC.
Patient instructions accompany all preparations detailing administration, dosage, and handling to ensure optimal therapeutic outcomes.
Pellets designed for mixing with non-acidic soft food or administration directly into the mouth to mask bitter taste and facilitate pediatric use.
Labeling includes medication guides emphasizing adherence, contraindications, potential side effects, and drug interaction warnings.